Medicus Pharma submits optimized Phase 2 study design for Teverelix

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to announce that the company has ...

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

Exclusive: Medicus Pharma refines trial design to cut costs, accelerate development for enlarged prostate patients

Medicus Pharma Ltd. MDCX said Monday it has submitted an optimized Phase 2 study design to the U.S. Food and Drug ...

Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA

Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US ...
The Caledonian-Record

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and ...